Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GALR2 | O43603 | 3/20 | 0.41 |
| ▸ | GALR1 | P47211 | 2/20 | 0.41 |
| ▸ | LCK | P06239 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CETP | P11597 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | IGF1R | P08069 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3246107 | 0.88 | CASP1 (0.44) | LMNAMAPTNPSR1HTTSMN1; SMN2 | |
| SCHEMBL8403164 | 0.83 | HTT (0.42) | GALR2GALR1LMNAMAPTHTT | |
| SCHEMBL3240502 | 0.78 | KMT2A (0.48) | GALR2GALR1LMNAMAPTRAB9A | |
| SCHEMBL1124030 | 0.76 | MAPT (0.45) | LMNAMAPTNPSR1HTTRAB9A | |
| SCHEMBL8254234 | 0.75 | MAPT (0.47) | GALR2GALR1LCKLMNAMAPT | |
| SCHEMBL8253240 | 0.75 | LMNA (0.47) | GALR2GALR1LCKLMNAMAPT | |
| SCHEMBL8104636 | 0.74 | GALR2 (0.50) | GALR2GALR1LMNAMAPTHTT | |
| SCHEMBL8263323 | 0.74 | GALR2 (0.59) | GALR2GALR1MAPTPOLBMEN1 | |
| SCHEMBL8088683 | 0.74 | KDM4E (0.47) | LMNAMAPTRAB9ASMN1; SMN2KDM4E | |
| SCHEMBL3790349 | 0.73 | EPHX2 (0.47) | LMNAMAPTSMN1; SMN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092570-A1 | GAL3 antagonists for the treatment of neuropathic pain | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2004-05-13 | — | — | US | disclosed |
| US-20040092570-A1 | GAL3 antagonists for the treatment of neuropathic pain | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092570-A1 | GAL3 antagonists for the treatment of neuropathic pain | GALR3, GALR2, GALR1 | GALR2 2/4885GALR1 3/4885LCK 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.